Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

FORMA Therapeutics Closes $25.5 Million Series B

publication date: Dec 1, 2009
FORMA Therapeutics, a pre-clinical stage Cambridge, MA biopharma, has closed a Series B financing that raised $25.5 million. The round was led by new investor Lilly Ventures, while existing investors Novartis Option Fund and Bio*One Capital of Singapore participated. Forma has established a laboratory in Beijing at Tsinghua University, headed by Yigong Shi, PhD, a molecular biologist who is Chair of the School of Medicine there. The company also has labs in Singapore and Connecticut. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital